About Young Women’s Forum (YW)
The YW Forum is dedicated towards the holistic approach of managing Breast cancer in Young women under the theme Managing Breast Cancer in Young Women
The forum will aim to bring the best clinical practices and scientific updates from global leaders, discuss difficult cases, understand multidisciplinary approach for young patients and participate in the discussion of current guidelines.
As the science is getting more robust with data and new findings, we hope this platform will fulfill the learning gap amongst healthcare professionals who manages young patients with BC.
Live Streaming
+
Video on Demand
(Post Event)

Virtual Meeting


Networking

Featuring Industry Partners & Products
Dear Colleagues,
It gives us immense pleasure to announce “Young Women’s Forum – YW” on 18th August, 2022 via Hybrid Meeting setup to kick off a niche but much needed discussion for the management of Breast Cancer in Young Women.
YW Committee envisions to bring attention to much needed focus that most young women with breast cancer have complex disease while they have many years ahead of them and the effect of treatment affects on their reproductive cycles, family life and careers and also that most of the treatment are based on clinical data from older women.
Therefore, with YW 2022 the scientific and organizing committee are committed to highlight the scientific based new evidences from global leaders, local perspectives and protocols in management of young women with breast cancer and also aims to foster collaborations by providing a panel for multidisciplinary teams to discuss difficult cases and build a future perspective for Asia Pacific and Middle East region.
The committee would like to welcome you all to initiate a meaningful forum to make a difference in young women’s life.
YW 2022 will once again take place in conjunction with the International BRCA Forum – iBRCAf 2022.
We welcome you to Singapore to learn and network with your colleagues & peers.
Kind Regards,
YW 2022 Committee Members

Our Committee Members

Rebecca Dent
Singapore

Shaheenah Dawood
UAE

Tira Tan
Singapore

Veronique Tan
Singapore

Andrea Wong
Singapore

Andrea Wong
Senior Consultant, Department of Haematology-Oncology
Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS). She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.
Sessions by this speaker
Thursday, 2021-08-12
Satellite Symposium - Novartis
13:30 - 14:00

Anne Partridge
USA

Anne Partridge
Medical Oncologist
Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Dr. Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference. She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. After graduating from Georgetown University, Dr. Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners CancerCare. She earned a Master of Public Health degree at the Harvard School of Public Health.
Lectures by this speaker
Thursday, 2021-08-12
Overview on Young Women with Breast Cancer
14:05 - 14:20
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Elaine Lim
Singapore

Elaine Lim
Senior Consultant
Dr Elaine Lim is Senior Consultant, Division of Medical Oncology at the National Cancer Centre, Singapore. Her interests are centred on breast, gynaecological and lung cancers. After graduating from Trinity College, University of Cambridge, Dr. Lim was selected to join the Cambridge MBBCh-PhD programme. Her PhD dissertation on molecular genetics was supervised by Nobel Laureate, Professor Sydney Brenner and Professor Timothy Cox. After completing her clinical training in Cambridge, Dr. Lim worked in London, which included the Royal London Hospital and the prestigious London ‘golden circuit’ of Hammersmith Hospital and Royal Brompton Hospital. Upon her return to Singapore, she joined the National University of Singapore (NUS) and National University Hospital (NUH) to pursue a career in Medical Oncology. She later moved to Johns Hopkins Singapore as Consultant in Medical Oncology, as well as being Visiting Consultant at Tan Tock Seng Hospital (TTSH) and Kandang Kerbau Women’s and Children’s Hospital (KKH). After a few years in private practice with Singapore Oncology Consultants, she joined the National Cancer Centre, Singapore, Division of Medical Oncology. She has continued her laboratory research activities in collaboration with the Genome Institute of Singapore and the Institute of Molecular and Cell Biology, and actively participates in clinical trials.
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Ellen Warner
Canada

Ellen Warner
Medical Oncologist
Dr. Ellen Warner is a medical oncologist at the Odette Cancer Centre of Sunnybrook Health Sciences Centre and a Professor of Medicine at the University of Toronto. She also holds a Masters degree in clinical epidemiology. Her clinical practice and research are entirely devoted to the management of women living with breast cancer or at high risk for developing the disease. Her main research interests are identification and screening of high risk women, management of breast cancer in very young women, and lifestyle factors that affect breast cancer recurrence and/or quality of life. Dr. Warner’s research led to the establishment of the Ontario Breast Screening Program’s High Risk program that offers annual MRI and mammography to women across Ontario at very high risk for developing breast cancer. She is also founder and director of Sunnybrook’s PYNK: Breast Cancer Program for Young – a clinical, research and educational program for women diagnosed with breast cancer at age 40 or younger.
Lectures by this speaker
Thursday, 2021-08-12
What is the Role of MRI Screening in Young Woman with Breast Cancer?
14:35 - 14:50
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Faye Lim
Singapore

Faye Lim
Senior Consultant
Dr Faye Lim graduated from the University of Nottingham Medical school and completed her Clinical Oncology Training at Mount Vernon Cancer Centre and University College Hospital. She is a senior consultant in the department of radiation oncology at the National Cancer Centre Singapore Her sub specialty includes breast and gastrointestinal cancers. She has a particular interest in the use of proton therapy in the treatment of breast cancer.
Sessions by this speaker
Thursday, 2021-08-12
Session 1: Diagnosing a Young Woman with Breast Cancer
14:05 - 15:05

Kim Hee-Jeong
Korea South

Kim Hee-Jeong
Associate Professor
.
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Lee Soo Chin
Singapore

Lee Soo Chin
Medical Oncologist
She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.
Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes
13:30 - 14:00
Thursday, 2021-08-12
Genomic Tests in Young Women
16:05 - 16:20
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05

Matteo Lambertini
Italy

Matteo Lambertini
Medical Oncologist
Matteo Lambertini is adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis. During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women. Thanks to the support of the European Society for Medical Oncology (ESMO), he has recently completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients.” With this work, he has contributed to improve our understanding of many controversial aspects related to the management of breast cancer in young women specifically focusing on fertility preservation and the possibility to have a pregnancy following treatment completion, with the ultimate goal to further improve the care and quality of life of these young women. He is member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embriology (ESHRE) and the Italian Association of Medical Oncology (AIOM). He has authored several publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy, the safety of having a pregnancy in women with prior history of breast cancer, and the impact of carrying a germline BRCA mutation on patients’ fertility and pregnancy-related issues.
Lectures by this speaker
Thursday, 2021-08-12
Optimal Endocrine Therapy and Duration of Therapy?
15:50 - 16:05
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05

Nirmala Bhoo Pathy
Malaysia

Nirmala Bhoo Pathy
Clinical Epidemiologist
Nirmala Bhoo-Pathy works as an Associate Professor of Epidemiology in the Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, and practices as a public health physician in University Malaya Medical Centre, Malaysia. She is also a visiting scholar at Queen’s University Belfast, United Kingdom since 2014. Dr Bhoo Pathy’s career is focused on optimizing life after cancer in resourcelimited settings through research and advocacy. She is particularly interested in the state of cancer control in the low- and middle-income countries, and enhancing treatment outcomes and patient-centered outcomes in these settings. Notably, Dr Bhoo Pathy was the principal investigator of phase III of the Asean CosTs In ONcology (ACTION) study, comprising close to 10,000 cancer patients from eight low-and middle-income member countries of the Association of South East Asian Nation (ASEAN). The study has been crucial in providing countryspecific evidence for Southeast Asian nations to prioritize policies and develop local solutions to reduce the financial loss and premature deaths associated with cancer. Dr Bhoo-Pathy currently serves in two Lancet Commissions, namely the Lancet Commission on Women and Cancer, and the Lancet Commission on Cancer and Health Systems. Besides her involvement in these commissions, she is a member of the Covid-19 and Cancer Taskforce, a globally representative group of cancer leaders who are gravely concerned that decisions made under the duress of the pandemic will have momentous consequences for cancer mortality for years to come https://covidcancertaskforce.org/ Nirmala Bhoo Pathy graduated as a medical doctor from University of Malaya, Malaysia in 2001. Following completion of her master’s degree in Public Health with distinction in 2008, she was awarded a fellowship by the European Commission, under which she completed a master’s degree in clinical epidemiology with cum laude, followed by a PhD (cancer epidemiology) from University of Utrecht, Netherlands in 2011.
Lectures by this speaker
Thursday, 2021-08-12
What Are the Unique Challenges Faced by Young Women with Breast Cancer in Asia?
14:20 - 14:35

Rebecca Dent
Singapore

Rebecca Dent
Medical Oncologist
Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials
Sessions by this speaker
Thursday, 2021-08-12
Welcome Note
14:00 - 14:05
Thursday, 2021-08-12
Session 1: Diagnosing a Young Woman with Breast Cancer
14:05 - 15:05
Thursday, 2021-08-12
Young Women Forum 2021
13:00 - 13:30

Shaheenah Dawood
United Arab Emirates

Shaheenah Dawood
Medical Oncologist
Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.
Sessions by this speaker
Thursday, 2021-08-12
Session 2: Challenging Cases in Young Women with Breast Cancer
15:05 - 15:50
Lectures by this speaker
Thursday, 2021-08-12
Closing Remarks
17:05 - 17:10

Shani Paluch-Shimon
Israel

Shani Paluch-Shimon
Medical Oncologist
Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.
Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches
13:00 - 13:30
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
Thursday, 2021-08-12
Options for Fertility Preservation
16:20 - 16:35
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05

Tira Tan
Singapore

Tira Tan
Consultant Medical Oncologist
Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.
Sessions by this speaker
Thursday, 2021-08-12
Session 3: Managing a Young Woman with Adjuvant Therapy
15:50 - 17:10
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Veronique Tan
Singapore

Veronique Tan
Head & Senior Consultant
Clinical Associate Professor Veronique Tan is a Senior Consultant and Chief of Breast Surgery at National Cancer Centre Singapore and Singapore General Hospital. She also Heads the SingHealth Duke-NUS Breast Centre. As one of the few breast surgeons in Singapore formally trained in oncoplastic breast surgery, A/Prof Tan believes that the appearance of the breast after cancer resection is important, and that every patient should have a tailored, individualised surgical solution. She works within a dynamic multidisciplinary team to deliver precise, high quality and effective treatment. A/Prof Tan’s practice covers benign breast conditions, the diagnosis and surgical treatment of symptomatic and screen-detected breast cancer, oncoplastic breast surgery and breast reconstruction. Active in research and teaching, A/Prof Tan has published numerous articles in peer-reviewed journals and contributed several book chapters on oncoplastic and reconstructive breast surgery.
Sessions by this speaker
Thursday, 2021-08-12
Session 3: Managing a Young Woman with Adjuvant Therapy
15:50 - 17:10

Yap Yoon Sim
Singapore

Yap Yoon Sim
Medical Oncologist
Dr. Yap is Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore, and Associate Professor at Duke-NUS Medical School. Dr. Yap obtained her undergraduate and postgraduate medical degrees from the University of Adelaide in Australia. She is a fellow of the Royal Australasian College of Physicians. Upon completion of her specialist training in medical oncology in Australia, she undertook a research fellowship with the Breast Unit at the Royal Marsden Hospital, London, before relocating to National Cancer Centre Singapore. A recipient of the Singapore National Medical Research Council (NMRC) Clinician Scientist Award (CSA), her research focuses primarily on clinical and translational research in breast cancer, including liquid biopsies and predictive biomarkers, development of novel therapeutic strategies, and epidemiologic studies on treatment outcomes in breast cancer. She is the principal investigator of several phase 1 to 3 clinical trials for various compounds such as CDK inhibitors, PI3K and mTOR inhibitors, selective estrogen receptor degraders, HER2-targeting agents and immunotherapy, in addition to investigator-initiated studies.
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
2021 Agenda
Event Day
12 August 2021
Young Women Forum 2021

Rebecca Dent
Medical Oncologist | Singapore
Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
The Neoadjuvant Therapy of TNBC – From Rags to Riches

Shani Paluch-Shimon
Medical Oncologist
Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.
Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches
13:00 - 13:30
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
Thursday, 2021-08-12
Options for Fertility Preservation
16:20 - 16:35
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
17:00 - 17:30
Satellite Symposium - Novartis

Andrea Wong
Senior Consultant, Department of Haematology-Oncology | Singapore
Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS). She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.
Sessions by this speaker
Thursday,
-
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes

Lee Soo Chin
Medical Oncologist
She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.
Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes
13:30 - 14:00
Thursday, 2021-08-12
Genomic Tests in Young Women
16:05 - 16:20
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
17:30 - 18:00
Welcome Note

Rebecca Dent
Medical Oncologist | Singapore
Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Session 1: Diagnosing a Young Woman with Breast Cancer

Rebecca Dent
Medical Oncologist | Singapore
Dr Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Centre Singapore and is Chief of the Breast Medical Oncology Service. She is also an Associate Professor at Duke-NUS Medical School. Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative/basal-like breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer, and is a steering committee member for a number of large international trials
Sessions by this speaker
Thursday,
-
Thursday,
-
Thursday,
-
Chairperson:

Faye Lim
Senior Consultant | Singapore
Dr Faye Lim graduated from the University of Nottingham Medical school and completed her Clinical Oncology Training at Mount Vernon Cancer Centre and University College Hospital. She is a senior consultant in the department of radiation oncology at the National Cancer Centre Singapore Her sub specialty includes breast and gastrointestinal cancers. She has a particular interest in the use of proton therapy in the treatment of breast cancer.
Sessions by this speaker
Thursday,
-
Overview on Young Women with Breast Cancer

Anne Partridge
Medical Oncologist
Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Dr. Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference. She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. After graduating from Georgetown University, Dr. Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners CancerCare. She earned a Master of Public Health degree at the Harvard School of Public Health.
Lectures by this speaker
Thursday, 2021-08-12
Overview on Young Women with Breast Cancer
14:05 - 14:20
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
18:05 - 18:20
What Are the Unique Challenges Faced by Young Women with Breast Cancer in Asia?

Nirmala Bhoo Pathy
Clinical Epidemiologist
Nirmala Bhoo-Pathy works as an Associate Professor of Epidemiology in the Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, and practices as a public health physician in University Malaya Medical Centre, Malaysia. She is also a visiting scholar at Queen’s University Belfast, United Kingdom since 2014. Dr Bhoo Pathy’s career is focused on optimizing life after cancer in resourcelimited settings through research and advocacy. She is particularly interested in the state of cancer control in the low- and middle-income countries, and enhancing treatment outcomes and patient-centered outcomes in these settings. Notably, Dr Bhoo Pathy was the principal investigator of phase III of the Asean CosTs In ONcology (ACTION) study, comprising close to 10,000 cancer patients from eight low-and middle-income member countries of the Association of South East Asian Nation (ASEAN). The study has been crucial in providing countryspecific evidence for Southeast Asian nations to prioritize policies and develop local solutions to reduce the financial loss and premature deaths associated with cancer. Dr Bhoo-Pathy currently serves in two Lancet Commissions, namely the Lancet Commission on Women and Cancer, and the Lancet Commission on Cancer and Health Systems. Besides her involvement in these commissions, she is a member of the Covid-19 and Cancer Taskforce, a globally representative group of cancer leaders who are gravely concerned that decisions made under the duress of the pandemic will have momentous consequences for cancer mortality for years to come https://covidcancertaskforce.org/ Nirmala Bhoo Pathy graduated as a medical doctor from University of Malaya, Malaysia in 2001. Following completion of her master’s degree in Public Health with distinction in 2008, she was awarded a fellowship by the European Commission, under which she completed a master’s degree in clinical epidemiology with cum laude, followed by a PhD (cancer epidemiology) from University of Utrecht, Netherlands in 2011.
Lectures by this speaker
Thursday, 2021-08-12
What Are the Unique Challenges Faced by Young Women with Breast Cancer in Asia?
14:20 - 14:35
18:20 - 18:35
What is the Role of MRI Screening in Young Woman with Breast Cancer?

Ellen Warner
Medical Oncologist
Dr. Ellen Warner is a medical oncologist at the Odette Cancer Centre of Sunnybrook Health Sciences Centre and a Professor of Medicine at the University of Toronto. She also holds a Masters degree in clinical epidemiology. Her clinical practice and research are entirely devoted to the management of women living with breast cancer or at high risk for developing the disease. Her main research interests are identification and screening of high risk women, management of breast cancer in very young women, and lifestyle factors that affect breast cancer recurrence and/or quality of life. Dr. Warner’s research led to the establishment of the Ontario Breast Screening Program’s High Risk program that offers annual MRI and mammography to women across Ontario at very high risk for developing breast cancer. She is also founder and director of Sunnybrook’s PYNK: Breast Cancer Program for Young – a clinical, research and educational program for women diagnosed with breast cancer at age 40 or younger.
Lectures by this speaker
Thursday, 2021-08-12
What is the Role of MRI Screening in Young Woman with Breast Cancer?
14:35 - 14:50
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
18:35 - 18:50
Question & Answers
18:50 - 19:05
Session 2: Challenging Cases in Young Women with Breast Cancer
Shaheenah Dawood | United Arab Emirates

Shaheenah Dawood
Medical Oncologist | United Arab Emirates
Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Panel Discussion

Tira Tan
Consultant Medical Oncologist
Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.
Sessions by this speaker
Thursday, 2021-08-12
Session 3: Managing a Young Woman with Adjuvant Therapy
15:50 - 17:10
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Elaine Lim
Senior Consultant
Dr Elaine Lim is Senior Consultant, Division of Medical Oncology at the National Cancer Centre, Singapore. Her interests are centred on breast, gynaecological and lung cancers. After graduating from Trinity College, University of Cambridge, Dr. Lim was selected to join the Cambridge MBBCh-PhD programme. Her PhD dissertation on molecular genetics was supervised by Nobel Laureate, Professor Sydney Brenner and Professor Timothy Cox. After completing her clinical training in Cambridge, Dr. Lim worked in London, which included the Royal London Hospital and the prestigious London ‘golden circuit’ of Hammersmith Hospital and Royal Brompton Hospital. Upon her return to Singapore, she joined the National University of Singapore (NUS) and National University Hospital (NUH) to pursue a career in Medical Oncology. She later moved to Johns Hopkins Singapore as Consultant in Medical Oncology, as well as being Visiting Consultant at Tan Tock Seng Hospital (TTSH) and Kandang Kerbau Women’s and Children’s Hospital (KKH). After a few years in private practice with Singapore Oncology Consultants, she joined the National Cancer Centre, Singapore, Division of Medical Oncology. She has continued her laboratory research activities in collaboration with the Genome Institute of Singapore and the Institute of Molecular and Cell Biology, and actively participates in clinical trials.
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Kim Hee-Jeong
Associate Professor
.
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Anne Partridge
Medical Oncologist
Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Dr. Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference. She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. After graduating from Georgetown University, Dr. Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners CancerCare. She earned a Master of Public Health degree at the Harvard School of Public Health.
Lectures by this speaker
Thursday, 2021-08-12
Overview on Young Women with Breast Cancer
14:05 - 14:20
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Ellen Warner
Medical Oncologist
Dr. Ellen Warner is a medical oncologist at the Odette Cancer Centre of Sunnybrook Health Sciences Centre and a Professor of Medicine at the University of Toronto. She also holds a Masters degree in clinical epidemiology. Her clinical practice and research are entirely devoted to the management of women living with breast cancer or at high risk for developing the disease. Her main research interests are identification and screening of high risk women, management of breast cancer in very young women, and lifestyle factors that affect breast cancer recurrence and/or quality of life. Dr. Warner’s research led to the establishment of the Ontario Breast Screening Program’s High Risk program that offers annual MRI and mammography to women across Ontario at very high risk for developing breast cancer. She is also founder and director of Sunnybrook’s PYNK: Breast Cancer Program for Young – a clinical, research and educational program for women diagnosed with breast cancer at age 40 or younger.
Lectures by this speaker
Thursday, 2021-08-12
What is the Role of MRI Screening in Young Woman with Breast Cancer?
14:35 - 14:50
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50

Shani Paluch-Shimon
Medical Oncologist
Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.
Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches
13:00 - 13:30
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
Thursday, 2021-08-12
Options for Fertility Preservation
16:20 - 16:35
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
19:05 - 19:50
Session 3: Managing a Young Woman with Adjuvant Therapy

Tira Tan
Consultant Medical Oncologist | Singapore
Dr Tira Tan is a consultant medical oncologist at the National Cancer Centre Singapore with a clinical focus in the treatment of breast cancers and early phase drug development. Dr Tan chairs the pre-operative and young women’s breast cancer programs at NCCS and is the primary and co-investigator on many early and late phase studies specifically in novel therapeutics and treatment strategies in triple negative breast cancer.
Sessions by this speaker
Thursday,
-
Lectures by this speaker
Thursday,
-
Chairperson:

Veronique Tan
Head & Senior Consultant | Singapore
Clinical Associate Professor Veronique Tan is a Senior Consultant and Chief of Breast Surgery at National Cancer Centre Singapore and Singapore General Hospital. She also Heads the SingHealth Duke-NUS Breast Centre. As one of the few breast surgeons in Singapore formally trained in oncoplastic breast surgery, A/Prof Tan believes that the appearance of the breast after cancer resection is important, and that every patient should have a tailored, individualised surgical solution. She works within a dynamic multidisciplinary team to deliver precise, high quality and effective treatment. A/Prof Tan’s practice covers benign breast conditions, the diagnosis and surgical treatment of symptomatic and screen-detected breast cancer, oncoplastic breast surgery and breast reconstruction. Active in research and teaching, A/Prof Tan has published numerous articles in peer-reviewed journals and contributed several book chapters on oncoplastic and reconstructive breast surgery.
Sessions by this speaker
Thursday,
-
Optimal Endocrine Therapy and Duration of Therapy?

Matteo Lambertini
Medical Oncologist
Matteo Lambertini is adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis. During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women. Thanks to the support of the European Society for Medical Oncology (ESMO), he has recently completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients.” With this work, he has contributed to improve our understanding of many controversial aspects related to the management of breast cancer in young women specifically focusing on fertility preservation and the possibility to have a pregnancy following treatment completion, with the ultimate goal to further improve the care and quality of life of these young women. He is member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embriology (ESHRE) and the Italian Association of Medical Oncology (AIOM). He has authored several publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy, the safety of having a pregnancy in women with prior history of breast cancer, and the impact of carrying a germline BRCA mutation on patients’ fertility and pregnancy-related issues.
Lectures by this speaker
Thursday, 2021-08-12
Optimal Endocrine Therapy and Duration of Therapy?
15:50 - 16:05
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
19:50 - 20:05
Genomic Tests in Young Women

Lee Soo Chin
Medical Oncologist
She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.
Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes
13:30 - 14:00
Thursday, 2021-08-12
Genomic Tests in Young Women
16:05 - 16:20
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
20:05 - 20:20
Options for Fertility Preservation

Shani Paluch-Shimon
Medical Oncologist
Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.
Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches
13:00 - 13:30
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
Thursday, 2021-08-12
Options for Fertility Preservation
16:20 - 16:35
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
20:20 - 20:35
Panel Discussion

Lee Soo Chin
Medical Oncologist
She is currently Head and Senior Consultant in Medical Oncology and Associate Director of Research at the National University Cancer Institute, Singapore, and Senior Principal Investigator at the Cancer Science Institute, Singapore. She is ex-Chairperson of the Chapter of Medical Oncologists, Academy of Medicine, Singapore, and has been a member of the Ministry of Health Specialist Accreditation Board for Medical Oncology since 2009. She has been Chair of the National Healthcare Group Domain-Specific Ethics Review Board B since 2008. She is also a member of the Singapore Ministry of Health Drug Advisory Committee for Oncology drugs. She specialises in breast cancer and directs the Cancer Genetics program at the National University Cancer Institute, Singapore. Her research focus is on breast cancer, pharmacogenetics and cancer genetics, and she has been the Principal Investigator of more than 40 industry-sponsored and investigator-initiated breast cancer clinical trials. She directs the Haematology-Oncology Research Group, a cancer clinical trials unit that conducts 100-120 phase I-III therapeutics clinical trials in solid tumours and haematological malignancies at the National University Cancer Institute.
Lectures by this speaker
Thursday, 2021-08-12
Overall Survival in Young Women with HR+/HER2- aBC and the Clinical Implication of Intrinsic Subtypes
13:30 - 14:00
Thursday, 2021-08-12
Genomic Tests in Young Women
16:05 - 16:20
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05

Matteo Lambertini
Medical Oncologist
Matteo Lambertini is adjunct professor and consultant in medical oncology at the IRCCS Policlinico San Martino Hospital – University of Genova in Genova (Italy). He is mainly focused in the care of breast cancer patients and is deeply involved in breast cancer research. Above all, he has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis. During his medical oncology training, he had the opportunity to work and collaborate with several national and international leading experts in the field; these experiences have played a crucial role to deepen his skills in the management of breast cancer in young women. Thanks to the support of the European Society for Medical Oncology (ESMO), he has recently completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy-related Issues in Young Breast Cancer Patients.” With this work, he has contributed to improve our understanding of many controversial aspects related to the management of breast cancer in young women specifically focusing on fertility preservation and the possibility to have a pregnancy following treatment completion, with the ultimate goal to further improve the care and quality of life of these young women. He is member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embriology (ESHRE) and the Italian Association of Medical Oncology (AIOM). He has authored several publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy, the safety of having a pregnancy in women with prior history of breast cancer, and the impact of carrying a germline BRCA mutation on patients’ fertility and pregnancy-related issues.
Lectures by this speaker
Thursday, 2021-08-12
Optimal Endocrine Therapy and Duration of Therapy?
15:50 - 16:05
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05

Shani Paluch-Shimon
Medical Oncologist
Dr Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. Dr Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee. Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.
Lectures by this speaker
Thursday, 2021-08-12
The Neoadjuvant Therapy of TNBC – From Rags to Riches
13:00 - 13:30
Thursday, 2021-08-12
Panel Discussion
15:05 - 15:50
Thursday, 2021-08-12
Options for Fertility Preservation
16:20 - 16:35
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05

Yap Yoon Sim
Medical Oncologist
Dr. Yap is Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore, and Associate Professor at Duke-NUS Medical School. Dr. Yap obtained her undergraduate and postgraduate medical degrees from the University of Adelaide in Australia. She is a fellow of the Royal Australasian College of Physicians. Upon completion of her specialist training in medical oncology in Australia, she undertook a research fellowship with the Breast Unit at the Royal Marsden Hospital, London, before relocating to National Cancer Centre Singapore. A recipient of the Singapore National Medical Research Council (NMRC) Clinician Scientist Award (CSA), her research focuses primarily on clinical and translational research in breast cancer, including liquid biopsies and predictive biomarkers, development of novel therapeutic strategies, and epidemiologic studies on treatment outcomes in breast cancer. She is the principal investigator of several phase 1 to 3 clinical trials for various compounds such as CDK inhibitors, PI3K and mTOR inhibitors, selective estrogen receptor degraders, HER2-targeting agents and immunotherapy, in addition to investigator-initiated studies.
Lectures by this speaker
Thursday, 2021-08-12
Panel Discussion
16:35 - 17:05
20:35 - 21:05
Closing Remarks
Shaheenah Dawood | United Arab Emirates

Shaheenah Dawood
Medical Oncologist
Dr. Shaheenah Dawood is a Consultant medical oncologist and associate professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the excellence In Oncology Care Congress that is held annually in Dubai and is co-president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and MENA immune-oncology summit.
Sessions by this speaker
Thursday, 2021-08-12
Session 2: Challenging Cases in Young Women with Breast Cancer
15:05 - 15:50
Lectures by this speaker
Thursday, 2021-08-12
Closing Remarks
17:05 - 17:10
21:05 - 21:10
View All Agenda
2021 Partners & Sponsors
Special thanks to the support, involvement and active contribution of our Partners and Sponsors.
DISCLAIMER: Young Women’s Forum (YWF) 2021 is virtual educational event for Asia Pacific Healthcare professionals. Mention of commercial products, processes, or services throughout the event cannot be construed as an endorsement or recommendation for viewers inside or outside the Asia Pacific Region. Information contained in this event is intended for educational purposes only, you are solely responsible for ensuring compliance with the laws of your specific jurisdiction.